Plasma Metabolome Normalization in Rheumatoid Arthritis Following Initiation of Methotrexate and the Identification of Metabolic Biomarkers of Efficacy

Methotrexate (MTX) efficacy in the treatment of rheumatoid arthritis (RA) is variable and unpredictable, resulting in a need to identify biomarkers to guide drug therapy. This study evaluates changes in the plasma metabolome associated with response to MTX in RA with the goal of understanding the metabolic basis for MTX efficacy towards the identification of potential metabolic biomarkers of MTX response. Plasma samples were collected from healthy control subjects (n = 20), and RA patients initiating MTX therapy (n = 20, 15 mg/week) before and after 16 weeks of treatment. The samples were analyzed by a semi-targeted metabolomic analysis, and then analyzed by univariate and multivariate methods, as well as an enrichment analysis. An MTX response was defined as a clinically significant reduction in the disease activity score in 28 joints (DAS-28) of greater than 1.2; achievement of clinical remission, defined as a DAS-28 < 2.6, was also utilized as an additional measure of response. In this study, RA is associated with an altered plasma metabolome that is normalized following initiation of MTX therapy. Metabolite classes found to be altered in RA and corrected by MTX therapy were diverse and included triglycerides (p = 1.1 × 10−16), fatty acids (p = 8.0 × 10−12), and ceramides (p = 9.8 × 10−13). Stratification based on responses to MTX identified various metabolites differentially impacted in responders and non-responders including glucosylceramides (GlcCer), phosphatidylcholines (PC), sphingomyelins (SM), phosphatidylethanolamines (PE), choline, inosine, hypoxanthine, guanosine, nicotinamide, and itaconic acid (p < 0.05). In conclusion, RA is associated with significant alterations to the plasma metabolome displaying at least partial normalization following 16 weeks of MTX therapy. Changes in multiple metabolites were found to be associated with MTX efficacy, including metabolites involved in fatty acid/lipid, nucleotide, and energy metabolism.

[1]  Lara A. Kahale,et al.  2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2021, Arthritis & rheumatology.

[2]  Lihua Zhang,et al.  Lipid Metabolism Profiles in Rheumatic Diseases , 2021, Frontiers in Pharmacology.

[3]  H. Sayles,et al.  Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate. , 2020, Seminars in Arthritis & Rheumatism.

[4]  M. Barrett,et al.  Changes in Plasma Itaconate Elevation in Early Rheumatoid Arthritis Patients Elucidates Disease Activity Associated Macrophage Activation , 2020, Metabolites.

[5]  G. Marsche,et al.  An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System , 2020, International journal of molecular sciences.

[6]  M. Guma,et al.  Circulating Pro- and Anti-Inflammatory Metabolites and Its Potential Role in Rheumatoid Arthritis Pathogenesis , 2020, Cells.

[7]  T. Aune,et al.  Methotrexate and its mechanisms of action in inflammatory arthritis , 2020, Nature Reviews Rheumatology.

[8]  K. Michaud,et al.  2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures , 2019, Arthritis care & research.

[9]  R. Singh,et al.  Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In Vitro , 2019, Clinical and translational science.

[10]  Markus M. Rinschen,et al.  Identification of bioactive metabolites using activity metabolomics , 2019, Nature Reviews Molecular Cell Biology.

[11]  Cheng Xiao,et al.  Treatment of Rheumatoid Arthritis Using Combination of Methotrexate and Tripterygium Glycosides Tablets—A Quantitative Plasma Pharmacochemical and Pseudotargeted Metabolomic Approach , 2018, Front. Pharmacol..

[12]  J. Schneider,et al.  Itaconic acid indicates cellular but not systemic immune system activation , 2018, Oncotarget.

[13]  N. Barbarroja,et al.  Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues , 2018, Journal of internal medicine.

[14]  C. Buckley,et al.  Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis , 2018, Arthritis & rheumatology.

[15]  Jian Ji,et al.  Software Tools and Approaches for Compound Identification of LC-MS/MS Data in Metabolomics , 2018, Metabolites.

[16]  N. Che,et al.  LC-MS-based serum metabolomics reveals a distinctive signature in patients with rheumatoid arthritis , 2018, Clinical Rheumatology.

[17]  O. Fiehn,et al.  Chemical Similarity Enrichment Analysis (ChemRICH) as alternative to biochemical pathway mapping for metabolomic datasets , 2017, Scientific Reports.

[18]  N. Jadavji,et al.  Impact of dietary supplementation of one-carbon metabolism on neural recovery , 2017, Neural regeneration research.

[19]  Yi Li,et al.  Succinate/NLRP3 Inflammasome Induces Synovial Fibroblast Activation: Therapeutical Effects of Clematichinenoside AR on Arthritis , 2016, Front. Immunol..

[20]  G. Kollias,et al.  Targeted Metabolic Profiling of the Tg197 Mouse Model Reveals Itaconic Acid as a Marker of Rheumatoid Arthritis. , 2016, Journal of proteome research.

[21]  Guowang Xu,et al.  Exploration of the serum metabolite signature in patients with rheumatoid arthritis using gas chromatography-mass spectrometry. , 2016, Journal of pharmaceutical and biomedical analysis.

[22]  J. Rathmell,et al.  A guide to immunometabolism for immunologists , 2016, Nature Reviews Immunology.

[23]  J. D. Sharer,et al.  Quantitative Analysis of Total Plasma Homocysteine by LC‐MS/MS , 2016, Current protocols in human genetics.

[24]  O. Fiehn.  Metabolomics by Gas Chromatography–Mass Spectrometry: Combined Targeted and Untargeted Profiling , 2016, Current protocols in molecular biology.

[25]  Monica Guma,et al.  Metabolomics in rheumatic diseases: desperately seeking biomarkers , 2016, Nature Reviews Rheumatology.

[26]  T. Finkel,et al.  Fatty acid oxidation in macrophage polarization , 2016, Nature Immunology.

[27]  Oliver Fiehn,et al.  Toward Merging Untargeted and Targeted Methods in Mass Spectrometry-Based Metabolomics and Lipidomics. , 2016, Analytical chemistry.

[28]  M. Becker,et al.  Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy , 2016 .

[29]  Carlos M. Laborde,et al.  Genomics, proteomics and metabolomics: their emerging roles in the discovery and validation of rheumatoid arthritis biomarkers. , 2015, Clinical and experimental rheumatology.

[30]  Y. Wettergren,et al.  Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages , 2014, Cancer Chemotherapy and Pharmacology.

[31]  H. Sayles,et al.  Unique Antibody Responses to Malondialdehyde-Acetaldehyde (MAA)-Protein Adducts Predict Coronary Artery Disease , 2014, PloS one.

[32]  L. O’Neill,et al.  Succinate: a metabolic signal in inflammation. , 2014, Trends in cell biology.

[33]  J. Manson,et al.  Biomarkers of one-carbon metabolism are associated with biomarkers of inflammation in women. , 2014, The Journal of nutrition.

[34]  T. Vos,et al.  The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study , 2014, Annals of the rheumatic diseases.

[35]  Jeffrey R Curtis,et al.  A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. , 2012, Arthritis and rheumatism.

[36]  Zhe Chen,et al.  1H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis , 2012 .

[37]  L. Qin,et al.  New Therapeutic Approaches for the Treatment of Rheumatoid Arthritis may Rise from the Cholinergic Anti-Inflammatory Pathway and Antinociceptive Pathway , 2010, TheScientificWorldJournal.

[38]  Oliver Fiehn,et al.  Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research , 2009, Metabolomics.

[39]  H. Cai,et al.  Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. Tracey,et al.  Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin , 2000, Nature.

[41]  R. D. Situnayake,et al.  Dyslipidaemia and rheumatoid arthritis , 1997 .

[42]  B. Myones,et al.  Dyslipoproteinemia in the course of active rheumatoid arthritis. , 1992, Seminars in arthritis and rheumatism.

[43]  S. Rantapää-Dahlqvist,et al.  Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. , 1991, Annals of the rheumatic diseases.

[44]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[45]  H. Lithell,et al.  Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. , 1987, Archives of internal medicine.

[46]  H. Lithell,et al.  Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. , 1987, Archives of internal medicine.

[47]  M. Sitkovsky,et al.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases , 2017, Nature Reviews Rheumatology.

[48]  P. V. van Riel.  The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). , 2014, Clinical and experimental rheumatology.

[49]  B. Cronstein,et al.  Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. , 2007, Bulletin of the NYU hospital for joint diseases.

[50]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.

[51]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[52]  T. Lundstedt,et al.  RESEARCH ARTICLE Open Access Diagnostic properties of metabolic perturbations in rheumatoid arthritis , 2022 .